Patricia Wallace, MD
Urogynecology and Reconstructive Pelvic Surgery · Mission Viejo, CANPI 1629162995
Payments from drug & device makers
Across 146 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$785
- AbbVie$384
- Caldera Medical, Inc$238
- Therapeuticsmd, Inc.$221
- Hologic Sales And Service, LLC$172
- Hollister Incorporated$157
- plus $829 from 18 others
What the payments were for
- Food & beverage$2,59693%
- Education$1666%
- Gifts$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 52 | $785 |
| AbbVie(2 entities) | 20 | $384 |
| Caldera Medical, Inc | 3 | $238 |
| Therapeuticsmd, Inc. | 18 | $221 |
| Hologic Sales And Service, LLC | 7 | $172 |
| Hollister Incorporated | 6 | $157 |
| Medtronic(2 entities) | 4 | $119 |
| Sumitomo Pharma America, Inc. | 4 | $108 |
| Acella Pharmaceuticals, LLC | 4 | $86 |
| Vertical Pharmaceuticals, LLC | 4 | $82 |
| Mayne Pharma Commercial LLC | 4 | $74 |
| Urovant Sciences Inc | 3 | $51 |
| ABC Home Medical Supply, Inc. | 2 | $47 |
| Coloplast | 3 | $42 |
| AMAG Pharmaceuticals, Inc. | 2 | $42 |
| Ascend Therapeutics US, LLC | 2 | $39 |
| Aspira Women's Health Inc | 1 | $25 |
| Millicent US Inc | 1 | $24 |
| Minerva Surgical, Inc | 1 | $16 |
| Myovant Sciences Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Pfizer | 1 | $15 |
| Electronic Waveform Lab, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$110
How this compares
$2,786 in reported general payments places this provider in the 35th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 102 | $104,939 |
| MyrbetriqMirabegron | 82 | $76,541 |
| Estradiol | 334 | $23,532 |
| EstringEstradiol | 27 | $14,308 |
| ProgesteroneProgesterone, Micronized | 114 | $5,645 |
| Methenamine Hippurate | 47 | $4,457 |
| ImvexxyEstradiol | 11 | $3,530 |
| Estradiol (Twice Weekly)Estradiol | 27 | $3,242 |
| Solifenacin Succinate | 60 | $2,812 |
| DottiEstradiol | 23 | $2,222 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 130 | $1,525 |
| Np ThyroidThyroid,pork | 37 | $1,382 |
| Cefdinir | 47 | $867 |
| Estradiol (Once Weekly)Estradiol | 13 | $864 |
| Cephalexin | 86 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $108 | $104,939102 claims |
| Astellas Pharma US IncMyrbetriq | $785 | $76,54182 claims |
| PfizerEstring | $15 | $14,30827 claims |
| Therapeuticsmd, Inc.Imvexxy | $221 | $3,53011 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $86 | $1,38237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Mission Viejo
- Bilal KaakiRiverside$431K
- Andrew BrillSan Francisco$345K
- Tanaz FerzandiLos Angeles$344K
- Savitha KrishnanMountain View$243K
- Felicia LaneOrange$121K
- Bruce Kahnla Jolla$114K
- Christopher TarnayLos Angeles$102K
- Peter CastilloLos Gatos$95K
- Azin ShahryarinejadManhattan Beach$90K
- Jennifer GruenenfelderOrange$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.